Novan (NASDAQ:NOVN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.53) by 26.42 percent. This is a 457.14 percent decrease over losses of $(0.07) per share from the same period last year.
Goldman Sachs Initiates Coverage On CinCor Pharma with Buy Rating, Announces Price Target of $67
Goldman Sachs analyst Madhu Kumar initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Buy rating and announces Price Target of $67.